Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC

NCT06424821 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

54

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Cadonilimab

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China